Nibrozetone

Nibrozetone
Clinical data
Other names	Rrx-001
Identifiers
	IUPAC name 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone;
CAS Number	925206-65-1;
PubChem CID	15950826;
DrugBank	DB12060;
ChemSpider	13092644;
UNII	7RPW6SU9SC;
KEGG	D12720;
ChEMBL	ChEMBL3526802;
Chemical and physical data
Formula	C5H6BrN3O5
Molar mass	268.023 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C(CN1C(=O)CBr)([N+](=O)[O-])[N+](=O)[O-];
	InChI InChI=InChI=1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2; Key:JODKFOVZURLVTG-UHFFFAOYSA-N;

Nibrozetone is an investigational new drug that is being evaluated by EpicentRx for the treatment of oral mucositis in head and neck cancer patients. It is a small molecule that combines direct inhibition of the NLRP3 inflammasome, induction of NRF2, and release of nitric oxide under hypoxic conditions.^[1]^[2] It has received Fast Track designation from the FDA for severe oral mucositis in head and neck cancer patients.^[3]

References

^ Oronsky B, Takahashi L, Gordon R, Cabrales P, Caroen S, Reid T (2023). "RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist". Frontiers in Oncology. 13: 1204143. doi:10.3389/fonc.2023.1204143. PMC 10258348. PMID 37313460.
^ Jayabalan N, Oronsky B, Cabrales P, Reid T, Caroen S, Johnson AM, et al. (April 2023). "A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation". Drugs. 83 (5): 389–402. doi:10.1007/s40265-023-01838-z. PMC 10015535. PMID 36920652.
^ Ryan C (30 March 2023). "FDA Grants Fast Track Designation to RRx-001 for Severe Oral Mucositis in Head and Neck Cancer". OncLive.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Oronsky_2023-1] Oronsky B, Takahashi L, Gordon R, Cabrales P, Caroen S, Reid T (2023). "RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist". Frontiers in Oncology. 13: 1204143. doi:10.3389/fonc.2023.1204143. PMC 10258348. PMID 37313460.

[pmid36920652-2] Jayabalan N, Oronsky B, Cabrales P, Reid T, Caroen S, Johnson AM, et al. (April 2023). "A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation". Drugs. 83 (5): 389–402. doi:10.1007/s40265-023-01838-z. PMC 10015535. PMID 36920652.

[3] Ryan C (30 March 2023). "FDA Grants Fast Track Designation to RRx-001 for Severe Oral Mucositis in Head and Neck Cancer". OncLive.

[1]

[2]

[3]